Building on BTK Inhibition in CLL
Anthony R. Mato, MD, MSCE, discusses recent treatment advances that have been made in the frontline and relapsed/refractory settings of chronic lymphocytic leukemia.
Related Articles
Five Under 5: Top Oncology Videos for the Week of 6/8
The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.
NAPOLI-3 Analysis Exposes Characteristics of Long-Term PDAC Survivors Treated With NALIRIFOX
A post hoc analysis of NAPOLI-3 reveals insights on long-term survivors with pancreatic cancer who received NALIRIFOX.
The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH
Alicia Morgans, MD, MPH, details the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide for this population.
SEQUOIA 5-year Follow-up in Arm C: Frontline Zanubrutinib Monotherapy in Patients with del(17p) and Treatment-naive CLL/SLL
Dr. Constantine S. Tam presents 5-year follow-up results from the SEQUOIA trial, showing that frontline zanubrutinib provides durable progression-free and overall survival with a consistent…
Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS
Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.
Obe-Cel and MRD Outcomes: Insights and Comparisons
Panelists discuss how real-world outcomes data from the CIBMTR registry on brexucabtagene autoleucel (brexu-cel) presented at the American Society of Hematology Annual Meeting and Exposition…
FDA Declines to Expand Label for Talazoparib/Enzalutamide in mCRPC
The FDA declined to expand the label for talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer.
Could Electric Fields Supercharge Immune Attack on the Deadliest Form of Brain Cancer?
Electric field device placed on the scalp, along with immunotherapy and chemotherapy may help patients with glioblastoma live longer, particularly those with large, inoperable tumors.
Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia
Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.
Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL
Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.